JP2014502149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502149A5 JP2014502149A5 JP2013538232A JP2013538232A JP2014502149A5 JP 2014502149 A5 JP2014502149 A5 JP 2014502149A5 JP 2013538232 A JP2013538232 A JP 2013538232A JP 2013538232 A JP2013538232 A JP 2013538232A JP 2014502149 A5 JP2014502149 A5 JP 2014502149A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- mutein
- gly
- trp
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000010956 Glypican Human genes 0.000 claims 5
- 108050001154 Glypican Proteins 0.000 claims 5
- 108050007237 Glypican-3 Proteins 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102000008300 Mutant Proteins Human genes 0.000 claims 3
- 108010021466 Mutant Proteins Proteins 0.000 claims 3
- 150000001875 compounds Chemical group 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical class N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 239000002184 metal Chemical class 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000013519 Lipocalin-2 Human genes 0.000 claims 1
- 108010051335 Lipocalin-2 Proteins 0.000 claims 1
- QTZXSYBVOSXBEJ-WDSKDSINSA-N Met-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O QTZXSYBVOSXBEJ-WDSKDSINSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000011616 biotin Chemical class 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000000824 cytostatic agent Chemical class 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical class C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 239000003053 toxin Chemical class 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41370610P | 2010-11-15 | 2010-11-15 | |
| EP10191228.5 | 2010-11-15 | ||
| EP10191228 | 2010-11-15 | ||
| US61/413,706 | 2010-11-15 | ||
| PCT/EP2011/070119 WO2012065978A1 (en) | 2010-11-15 | 2011-11-15 | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502149A JP2014502149A (ja) | 2014-01-30 |
| JP2014502149A5 true JP2014502149A5 (OSRAM) | 2015-01-08 |
| JP6100694B2 JP6100694B2 (ja) | 2017-03-22 |
Family
ID=45346426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538232A Expired - Fee Related JP6100694B2 (ja) | 2010-11-15 | 2011-11-15 | グリピカン−３（ｇｐｃ３）に対して親和性を有するヒトリポカリン２の突然変異タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9260492B2 (OSRAM) |
| EP (1) | EP2640740B1 (OSRAM) |
| JP (1) | JP6100694B2 (OSRAM) |
| AU (1) | AU2011331232B2 (OSRAM) |
| CA (1) | CA2817779C (OSRAM) |
| DK (1) | DK2640740T3 (OSRAM) |
| WO (1) | WO2012065978A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549968B2 (en) * | 2009-12-07 | 2017-01-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target |
| DK2640740T3 (en) | 2010-11-15 | 2017-06-26 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) |
| US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| CA2891557A1 (en) | 2013-03-26 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| CN113621050A (zh) * | 2014-05-22 | 2021-11-09 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
| US11382963B2 (en) * | 2015-01-12 | 2022-07-12 | Pieris Pharmaceuticals Gmbh | Engineered T cells and uses therefor |
| SG10201906859PA (en) | 2015-01-28 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| US11261221B2 (en) | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| CN107636014B (zh) | 2015-05-04 | 2021-12-07 | 皮里斯制药有限公司 | 抗癌融合多肽 |
| FI3298030T3 (fi) | 2015-05-18 | 2023-02-22 | Pieris Pharmaceuticals Gmbh | Syöpää ehkäisevä fuusiopolypeptidi |
| CN107787327B (zh) * | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白 |
| EP3115066A1 (en) * | 2015-07-07 | 2017-01-11 | Technische Universität München | Novel psma-specific binding proteins |
| ES2809125T3 (es) * | 2015-09-23 | 2021-03-03 | Bristol Myers Squibb Co | Moléculas de armazón a base de fibronectina de unión a glipicano-3 |
| SG11201803732PA (en) | 2015-11-30 | 2018-06-28 | Pieris Australia Pty Ltd | Novel anti-angiogenic fusion polypeptides |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| ES3015117T3 (en) | 2016-08-29 | 2025-04-29 | Fred Hutchinson Cancer Center | Chelating platform for delivery of radionuclides |
| JP2021506329A (ja) | 2017-12-20 | 2021-02-22 | ザンクト アンナ キンダークレプスフォルシュング | リガンド制御したタンパク質−タンパク質相互作用システム |
| EP3502130A1 (en) | 2017-12-20 | 2019-06-26 | St. Anna Kinderkrebsforschung | Ligand regulated protein-protein interaction system |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| IL297495A (en) | 2020-04-22 | 2022-12-01 | Dragonfly Therapeutics Inc | Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins |
| CN116249709A (zh) | 2020-06-05 | 2023-06-09 | 皮里斯制药有限公司 | 靶向4-1bb的多聚体免疫调节剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| PL192364B1 (pl) | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7235520B2 (en) * | 2000-09-21 | 2007-06-26 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP2899277A1 (en) * | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| RS54624B1 (sr) | 2007-07-17 | 2016-08-31 | E. R. Squibb & Sons, L.L.C. | Monoklonska antitela protiv glipikana-3 |
| EP2313430B1 (en) * | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| DK2640740T3 (en) | 2010-11-15 | 2017-06-26 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) |
-
2011
- 2011-11-15 DK DK11794661.6T patent/DK2640740T3/en active
- 2011-11-15 JP JP2013538232A patent/JP6100694B2/ja not_active Expired - Fee Related
- 2011-11-15 WO PCT/EP2011/070119 patent/WO2012065978A1/en not_active Ceased
- 2011-11-15 US US13/885,229 patent/US9260492B2/en active Active
- 2011-11-15 CA CA2817779A patent/CA2817779C/en active Active
- 2011-11-15 EP EP11794661.6A patent/EP2640740B1/en active Active
- 2011-11-15 AU AU2011331232A patent/AU2011331232B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502149A5 (OSRAM) | ||
| JP2018532372A5 (OSRAM) | ||
| JP6475630B2 (ja) | ストレプトアビジン突然変異タンパク質およびそれらを使用する方法 | |
| CN110437320B (zh) | 多肽 | |
| JP2017518748A5 (OSRAM) | ||
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| JP2013512683A5 (OSRAM) | ||
| JP2018519802A5 (OSRAM) | ||
| RU2015137158A (ru) | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ | |
| US8426557B2 (en) | IGF-1R binding polypeptides and their use | |
| JP2018515084A5 (OSRAM) | ||
| JP2019506140A5 (OSRAM) | ||
| RU2714156C2 (ru) | С5-связующие полипептиды | |
| JP2020505948A5 (OSRAM) | ||
| RU2019122482A (ru) | Мутеины липокалина с аффинностью связывания в отношении lag-3 | |
| US7993848B2 (en) | Staphylococcus protein A domain mutants that bind to TNF-α | |
| JP2019163270A (ja) | 親和性タンパク質及びその使用 | |
| JP2019527033A5 (OSRAM) | ||
| JP2004501605A5 (OSRAM) | ||
| JP7553433B2 (ja) | 抗ヒト心筋トロポニンｉの抗体及びその使用 | |
| JP2007535293A5 (OSRAM) | ||
| Kawabata et al. | Peptide-based immunoadsorbents: Molecular grafting of IgG–Fc-binding epitopes of Protein A onto a de novo-designed helix-loop-helix peptide | |
| Nice et al. | Strategies for the identification and purification of ligands for orphan biomolecules | |
| WO2013148583A1 (en) | Binding proteins to the constant region of immunoglobulin g | |
| CN116199746A (zh) | 高亲和力靶向Trop2的多元环肽分子框架 |